gamma-aminobutyric acid and Huntington Disease studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research Excerpts

Excerpt	Relevance	Reference
"We describe clinical and biochemical changes in seven patients with Huntington disease given isoniazid (INH) in dosages three to five greater than normally used in tuberculosis."	9.04	Isoniazid therapy of Huntington disease. ( Hansen, S; MacLeod, PM; Perry, TL; Wright, JM, 1979)
"The interaction of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) with erythrocyte membranes from patients with Huntington disease and normal controls has been studied by electron spin resonance."	7.66	Erythrocyte membrane alterations in Huntington disease: effects of gamma-aminobutyric acid. ( Braden, ML; Butterfield, DA; Markesbery, WR, 1978)
"We describe clinical and biochemical changes in seven patients with Huntington disease given isoniazid (INH) in dosages three to five greater than normally used in tuberculosis."	5.04	Isoniazid therapy of Huntington disease. ( Hansen, S; MacLeod, PM; Perry, TL; Wright, JM, 1979)
"The alteration in circulating levels of PRL, GH, TSH, and cortisol was studied after the oral administration of muscimol (3-hydroxy-5-aminomethylisoxazole) to human subjects with Huntington's disease (n = 4) and chronic schizophrenia (n = 5)."	3.66	Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. ( Chase, TN; Frohman, LA; Neophytides, A; Tamminga, CA, 1978)
"The interaction of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) with erythrocyte membranes from patients with Huntington disease and normal controls has been studied by electron spin resonance."	3.66	Erythrocyte membrane alterations in Huntington disease: effects of gamma-aminobutyric acid. ( Braden, ML; Butterfield, DA; Markesbery, WR, 1978)
"Treatment with isoniazid had no significant effect on CSF choline levels or CSF AChE activity."	2.67	Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease. ( Colliver, JA; Giacobini, E; Manyam, BV, 1990)
"Hereditary Huntington's disease (HD) is characterized by cell dysfunction and death in the brain, leading to progressive cognitive, psychiatric, and motor impairments."	2.58	Alteration of GABAergic neurotransmission in Huntington's disease. ( Baufreton, J; Chazalon, M; Cho, YH; Du, Z; Garret, M, 2018)
"Huntington disease is a neurological autosomal dominant disease of unknown origin and the search for a suitable diagnostic marker has been extended to the peripheral tissues."	2.37	The current state of research with peripheral tissues in Huntington disease. ( Beverstock, GC, 1984)
"Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function."	2.36	Pharmacology of GABA. ( Meldrum, B, 1982)
"The dichotomy of Parkinson's disease; akinesia with increased tone, and the mirror effects in Huntington's disease; hemiballismus and tardive dyskinesia, hyperkinesia with decreased tone are explained as due to two outputs of the system with an intervening inhibitory neuron which reverses the sign."	2.36	The basal ganglia in extrapyramidal dysfunction. ( Barnes, CD, 1983)
"Huntington's chorea is a dominantly inherited disorder that usually leads to involuntary movements in the third or fourth decade."	2.36	Neurochemical findings in Huntington's chorea. ( Bird, ED; Iversen, LL, 1977)
"Huntington Disease is autosomal, fatal and progressive neurodegenerative disorder for which clinically available drugs offer only symptomatic relief."	1.46	Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation. ( Deshmukh, R; Gill, JS; Jamwal, S; Kumar, P, 2017)
"Quinolinic acid (QA) is an excitotoxin that induces Huntington's-like symptoms in animals and humans."	1.43	Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats. ( Kumar, P; Singh, S, 2016)
"Curcumin (CMN) is a well-known antioxidant but the major problem is its bioavailability."	1.43	Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats. ( Kumar, P; Singh, S, 2016)
"Many genetic mouse models of Huntington's disease (HD) have established that mutant huntingtin (htt) accumulates in various subcellular regions to affect a variety of cellular functions, but whether and how synaptic mutant htt directly mediates HD neuropathology remains to be determined."	1.39	Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms. ( Gaertig, MA; Huang, S; Li, H; Li, S; Li, XJ; Liu, X; Song, M; Wang, CE; Xu, Q; Yan, S; Yu, SP, 2013)
"Huntington's disease is a progressive neurodegenerative disorder that gradually reduces memory, cognitive skills and normal movements of affected individuals."	1.38	Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. ( Kalonia, H; Kumar, A; Kumar, P, 2012)
"It is able to simulate the normal and Huntington's disease stride time intervals."	1.35	Huntington's disease: modeling the gait disorder and proposing novel treatments. ( Banaie, M; Gharibzadeh, S; Sarbaz, Y; Towhidkhah, F, 2008)
"Huntington's disease is a movement disorder originated from malfunctioning of Basal Ganglia (BG)."	1.35	Huntington's disease: modeling the gait disorder and proposing novel treatments. ( Banaie, M; Gharibzadeh, S; Sarbaz, Y; Towhidkhah, F, 2008)
"In summary, arvanil does alleviate hyperkinesia typical of HD, although it also affects locomotion in normal rats."	1.33	Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. ( de Lago, E; Di Marzo, V; Fernández-Ruiz, J; Ramos, JA; Urbani, P, 2005)
"Taurine pretreatment also caused about 2-fold increase in GABA concentration compared to 3-NP-treated animals."	1.33	Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. ( Abdel-Naim, AB; Arafa, HM; Khalifa, AE; Tadros, MG, 2005)
"Taurine is a semi-essential beta-amino acid that was demonstrated to have both antioxidant and GABA-A agonistic activity."	1.33	Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. ( Abdel-Naim, AB; Arafa, HM; Khalifa, AE; Tadros, MG, 2005)
"An experimental animal model of Huntington's disease (HD) phenotype was induced using the mycotoxin 3-nitropropionic acid (3-NP) and was well characterized behaviorally, neurochemically, morphometrically and histologically."	1.33	Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. ( Abdel-Naim, AB; Arafa, HM; Khalifa, AE; Tadros, MG, 2005)
"Huntington's disease is an autosomal dominant disease which presents with striatal and cortical degeneration causing involuntary movements, dementia and emotional changes."	1.31	Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. ( Brundin, P; Hansson, O; Haraldsson, B; Nicniocaill, B; O'Connor, WT, 2001)
"Huntington's disease is an incurable genetic neurological disorder characterized by the relatively selective degeneration of the striatum."	1.30	The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. ( Alexi, T; Clark, RG; Faull, RL; Gluckman, PD; Hughes, PE; van Roon-Mom, WM; Williams, CE, 1999)
"Huntington disease is characterized by the selective loss of striatal neurons, particularly of medium-sized spiny glutamate decarboxylase67 staining/GABAergic projection neurons which co-contain the calcium binding protein calbindin."	1.30	Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. ( Alexi, T; Clark, RG; Gluckman, PD; Hughes, PE; Williams, CE, 1999)
"Using this animal model of human Huntington's disease we investigated the effect of daily intrastriatal infusion of the nerve cell survival molecule ActivinA (single bolus dose of 0."	1.30	Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. ( Alexi, T; Clark, RG; Gluckman, PD; Hughes, PE; Williams, CE, 1999)
"Using this animal model of Huntington's disease, we investigated the ability of the insulin-like growth factor-I (IGF-I) amino-terminal tripeptide glycine-proline-glutamate (GPE) to protect striatal neurons from degeneration."	1.30	The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. ( Alexi, T; Clark, RG; Faull, RL; Gluckman, PD; Hughes, PE; van Roon-Mom, WM; Williams, CE, 1999)
"Huntington's disease is a progressive degenerative neurological disorder which produces a characteristic movement disorder termed chorea."	1.29	Neurochemical substrates of rigidity and chorea in Huntington's disease. ( Beal, MF; Storey, E, 1993)
"We also characterized changes in the Huntington's disease patients according to pathological grade, since this may be a confounding factor."	1.29	Neurochemical substrates of rigidity and chorea in Huntington's disease. ( Beal, MF; Storey, E, 1993)
"A patient with adult onset Huntington's disease (HD) and prominent action myoclonus is described."	1.29	Adult onset myoclonic Huntington's disease. ( Binelli, S; Carella, F; Ciano, C; Girotti, F; Oliva, D; Scaioli, V, 1993)
"Huntington's disease is a progressive neurodegenerative disease in which the basal ganglia are preferentially affected."	1.28	The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex. ( Beal, MF; Finn, SF; Kowall, NW; Mazurek, MF; Storey, E, 1992)
"Putamen tissue from four cases of Huntington's disease showed a marked reduction in [3H]nipecotic acid binding."	1.28	[3H]nipecotic acid binding to gamma-aminobutyric acid uptake sites in postmortem human brain. ( Czudek, C; Reynolds, GP, 1990)
"Neurochemical correlates of chorea in Huntington's disease were studied using striatal and pallidal tissue taken post mortem from patients with mild and severe chorea."	1.28	Pallidal GABA and chorea in Huntington's disease. ( Heathfield, KW; Pearson, SJ; Reynolds, GP, 1990)
"In patients with Huntington's disease, on administration of isoniazid at 900 mg/day, along with pyridoxine at 100 mg/day, a 4-fold increase of both free (P less than 0."	1.27	Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. ( Manyam, BV; Tremblay, RD, 1984)
"gamma-Aminobutyric acid (GABA) was measured in CSF as such and following acid hydrolysis by the ion-exchange/fluorometric method."	1.27	Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. ( Manyam, BV; Tremblay, RD, 1984)
"The previously reported loss of GABA in Huntington's disease was confirmed, while no change in dopamine concentrations and a loss of homovanillic acid in these striatal regions were observed."	1.27	Striatal dopamine and homovanillic acid in Huntington's disease. ( Garrett, NJ; Reynolds, GP, 1986)
"Values found in Friedreich's ataxia or Parkinson's disease were not significantly different from those in controls."	1.27	Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea. ( Agid, Y; Bonnet, AM; De Smet, Y; Grove, J; Saint-Hilaire, MH; Schechter, PJ; Tell, G, 1987)
"Patients with Huntington's chorea showed an increase in body movements during sleep."	1.27	[Disorders of nocturnal sleep in Huntington chorea]. ( Iakhno, NN, 1985)
"Gamma-aminobutyric acid (GABA) was measured by the ion-exchange fluorometric method in CSF from 22 individuals at risk for Huntington's disease (HD), six individuals with HD, and five neurologically normal controls."	1.26	Huntington's disease. Cerebrospinal fluid GABA levels in at-risk individuals. ( Glaeser, BS; Hare, TA; Katz, L; Manyam, NV, 1978)
"Huntington's disease (Huntington's chorea), a degenerative disorder of the central nervous system, is inherited in an autosomal dominant pattern."	1.26	Huntington's disease: current concepts of therapy. ( Goetz, CG; Weiner, WJ, 1979)
"Gamma-aminobutyric acid (G."	1.26	Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. ( Buchanan, J; Hansen, S; Kish, SJ; Perry, TL, 1979)
"[3H]GABA binding (IC50) was altered in Huntington's chorea and Reye's syndrome, but not in schizophrenics (4-neuroleptic-treated patients) or sudden infant death syndrome."	1.26	An analysis of [3H]gamma-aminobutyric acid (GABA) binding in the human brain. ( Dreksler, S; Lloyd, KG, 1979)
"Neuropathologically, Huntington's disease is characterized by a profound reduction in neuronal cells originating in the corpus striatum and globus pallidus."	1.26	Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. ( Enna, SJ; Stern, LZ; Wastek, GJ; Yamamura, HI, 1977)

Research

Studies (214)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort.

Timeframe	Studies, this research(%)	All Research%
pre-1990	141 (65.89)	18.7374
1990's	16 (7.48)	18.2507
2000's	33 (15.42)	29.6817
2010's	22 (10.28)	24.3611
2020's	2 (0.93)	2.80

Authors	Studies
Barry, J	2
Sarafian, TA	1
Watson, JB	1
Cepeda, C	3
Levine, MS	3
Le Cann, K	1
Foerster, A	1
Rösseler, C	1
Erickson, A	1
Hautvast, P	1
Giesselmann, S	1
Pensold, D	1
Kurth, I	1
Rothermel, M	1
Mattis, VB	1
Zimmer-Bensch, G	1
von Hörsten, S	2
Denecke, B	1
Clarner, T	1
Meents, J	1
Lampert, A	1
Alpaugh, M	1
Galleguillos, D	1
Forero, J	1
Morales, LC	1
Lackey, SW	1
Kar, P	1
Di Pardo, A	1
Holt, A	1
Kerr, BJ	1
Todd, KG	1
Baker, GB	1
Fouad, K	1
Sipione, S	1
Dargaei, Z	1
Bang, JY	1
Mahadevan, V	1
Khademullah, CS	1
Bedard, S	1
Parfitt, GM	1
Kim, JC	1
Woodin, MA	1
Garret, M	2
Du, Z	2
Chazalon, M	2
Cho, YH	2
Baufreton, J	2
Jamwal, S	2
Kumar, P	4
Petrella, LI	1
Castelhano, JM	1
Ribeiro, M	1
Sereno, JV	1
Gonçalves, SI	1
Laço, MN	1
Hayden, MR	1
Rego, AC	1
Castelo-Branco, M	1
Akopian, G	1
Hsu, YT	2
Chang, YG	2
Chern, Y	2
Perez-Rosello, T	1
Gelman, S	1
Tombaugh, G	1
Cachope, R	1
Beaumont, V	1
Surmeier, DJ	1
Liu, YC	1
Wang, KY	1
Chen, HM	1
Lee, DJ	1
Yang, SS	1
Tsai, CH	1
Lien, CC	1
Xu, Q	1
Huang, S	1
Song, M	1
Wang, CE	1
Yan, S	1
Liu, X	1
Gaertig, MA	1
Yu, SP	1
Li, H	1
Li, S	1
Li, XJ	1
Wójtowicz, AM	1
Dvorzhak, A	2
Semtner, M	2
Grantyn, R	2
Martínez-Lazcano, JC	2
Montes, S	2
Sánchez-Mendoza, MA	1
Rodríguez-Páez, L	1
Pérez-Neri, I	2
Boll, MC	1
Campos-Arroyo, HD	1
Ríos, C	2
Pérez-Severiano, F	3
Philpott, AL	1
Cummins, TDR	1
Bailey, NW	1
Churchyard, A	1
Fitzgerald, PB	1
Georgiou-Karistianis, N	1
Singh, S	1
Morales-Martínez, A	1
Sánchez-Mendoza, A	1
Pineda-Farías, JB	1
El-Hafidi, M	1
Martínez-Gopar, PE	1
Tristán-López, L	1
Zamorano-Carrillo, A	1
Castro, N	1
Bestaven, E	1
Leste-Lasserre, T	1
Cazalets, JR	1
Gill, JS	1
Deshmukh, R	1
Banaie, M	2
Sarbaz, Y	2
Gharibzadeh, S	2
Towhidkhah, F	2
Tsang, TM	1
Haselden, JN	1
Holmes, E	1
Allen, KL	1
Waldvogel, HJ	1
Glass, M	1
Faull, RL	3
Kalonia, H	1
Kumar, A	1
Chiodi, V	1
Uchigashima, M	1
Beggiato, S	1
Ferrante, A	1
Armida, M	1
Martire, A	1
Potenza, RL	1
Ferraro, L	1
Tanganelli, S	1
Watanabe, M	1
Domenici, MR	1
Popoli, P	1
Hashimoto, K	1
Ito, Y	1
Tanahashi, H	1
Hayashi, M	1
Yamakita, N	1
Yasuda, K	1
McLeod, MC	1
Kobayashi, NR	1
Sen, A	1
Baghbaderani, BA	1
Sadi, D	1
Ulalia, R	1
Behie, LA	1
Mendez, I	1
Faber, DS	1
Kanazawa, I	3
Lastres-Becker, I	3
de Miguel, R	2
De Petrocellis, L	1
Makriyannis, A	1
Di Marzo, V	3
Fernández-Ruiz, J	5
Marti, M	2
Mela, F	1
Ulazzi, L	1
Hanau, S	1
Stocchi, S	1
Paganini, F	1
Beani, L	1
Bianchi, C	1
Morari, M	2
Alfinito, PD	1
Wang, SP	1
Manzino, L	1
Rijhsinghani, S	1
Zeevalk, GD	1
Sonsalla, PK	1
Saulle, E	1
Gubellini, P	1
Picconi, B	1
Centonze, D	2
Tropepi, D	1
Pisani, A	1
Rossi, L	1
Papa, M	1
Bernardi, G	2
Calabresi, P	2
Reiner, A	1
Kells, AP	2
Fong, DM	1
Dragunow, M	1
During, MJ	1
Young, D	1
Connor, B	2
Tattersfield, AS	1
Croon, RJ	1
Liu, YW	1
Zucker, B	1
Ludin, DE	1
Gerds, TA	1
Lücking, CH	1
Landwehrmeyer, GB	1
Feuerstein, TJ	1
Berghuis, P	1
Dobszay, MB	1
Ibanez, RM	1
Ernfors, P	1
Harkany, T	1
Bosch, M	1
Pineda, JR	1
Suñol, C	1
Petriz, J	1
Cattaneo, E	1
Alberch, J	1
Canals, JM	1
Starling, AJ	1
Wu, N	1
Nguyen, OK	1
Uzgil, B	1
Soda, T	1
André, VM	1
Ariano, MA	1
Lee, ST	1
Chu, K	1
Park, JE	1
Lee, K	1
Kang, L	1
Kim, SU	1
Kim, M	1
Rossi, S	1
Prosperetti, C	1
Tscherter, A	1
Maccarrone, M	1
de Lago, E	2
Urbani, P	1
Ramos, JA	4
Burton, A	1
Ortega-Gutiérrez, S	1
Cabranes, A	1
Pryce, G	1
Baker, D	1
López-Rodríguez, M	1
Pérez-De La Cruz, V	1
González-Cortés, C	1
Galván-Arzate, S	1
Medina-Campos, ON	1
Ali, SF	1
Pedraza-Chaverrí, J	1
Santamaría, A	1
Tadros, MG	1
Khalifa, AE	1
Abdel-Naim, AB	1
Arafa, HM	1
Wu, J	1
Tang, T	1
Bezprozvanny, I	1
Bode, FJ	1
Stephan, M	1
Suhling, H	1
Pabst, R	1
Straub, RH	1
Raber, KA	1
Bonin, M	1
Nguyen, HP	1
Riess, O	1
Bauer, A	1
Sjoberg, C	1
Petersén, A	1
Young, AB	2
Pan, HS	1
Ciliax, BJ	1
Penney, JB	2
Shoulson, I	3
Reisine, TD	1
Overstreet, D	1
Gale, K	2
Rossor, M	3
Iversen, L	1
Yamamura, HI	3
Lloyd, KG	7
Worms, P	1
Wray, SR	1
Melville, GN	1
Grell, GA	1
Edge, PC	1
Casu, M	1
Rossor, MN	2
Kish, SJ	4
Shannak, KS	1
Perry, TL	12
Hornykiewicz, O	2
Scheel-Krüger, J	1
Martin, JB	1
Yamamoto, M	1
Otsuki, S	1
Miyake, K	1
Namba, R	1
Meldrum, B	1
McLean, DR	1
Cross, A	1
Levin, SL	1
Sytinskiĭ, IA	1
Kuroda, H	1
Durso, R	1
Tamminga, CA	2
Denaro, A	1
Ruggeri, S	1
Chase, TN	4
Ferraro, TN	2
Manyam, BV	5
Hare, TA	8
Barnes, CD	1
Barbosa, ER	1
Marchiori, PE	1
Scaff, M	1
de Assis, JL	1
Christensen, SE	1
Dupont, E	1
Mondrup, K	1
Olivarius, BF	1
Orskov, H	1
Waddington, JL	2
Cross, AJ	2
Korczyn, AD	1
Eshel, Y	1
Göhlich, G	1
Kuhn, W	1
Höhn, H	1
Przuntek, H	1
Puca, FM	1
Genco, S	1
Minervini, MG	1
Specchio, LM	1
Napoletano, V	1
Brancasi, B	1
Reggio, F	1
Tremblay, RD	2
Nakamura, S	1
Ito, M	1
Jones, K	1
Hansen, S	10
Olsen, RW	2
Van Ness, P	1
Napias, C	1
Bergman, M	1
Tourtellotte, WW	2
Butterfield, DA	2
Markesbery, WR	2
Brennan, MJ	1
van der Westhuyzen, J	1
Kramer, S	1
Metz, J	1
Hamel, E	1
Goetz, IE	1
Roberts, E	2
Van Ness, PC	1
Watkins, AE	1
Bergman, MO	1
Bartholini, G	2
Beverstock, GC	1
Robin, MM	1
Palfreyman, MG	1
Zraika, MM	1
Schechter, PJ	2
Manyam, NV	3
Katz, L	4
Bird, ED	8
Gerber, JC	1
Grossman, MH	1
Klawans, HL	3
Goetz, CG	2
Perlik, S	2
Spokes, EG	3
Garrett, NJ	3
Iversen, LL	7
Enna, SJ	5
MacLean, J	1
Berry, K	1
Benarroch, EE	1
Kaniefski, K	1
Ando, K	1
Wall, RA	2
Gauthier, SG	1
Marsden, CD	1
Sheehy, MP	1
Fisher, RH	1
Norris, JW	1
DeManuele, F	1
Ridgley, B	1
Malyon, C	1
Storey, E	2
Beal, MF	3
Carella, F	1
Scaioli, V	1
Ciano, C	1
Binelli, S	1
Oliva, D	1
Girotti, F	2
Reynolds, NC	1
Lin, W	1
Meyer Cameron, C	1
Roerig, DL	1
Reynolds, GP	7
Dalton, CF	1
Tillery, CL	1
Mangiarini, L	1
Davies, SW	1
Bates, GP	1
Hughes, PE	2
Alexi, T	2
Williams, CE	2
Clark, RG	2
Gluckman, PD	2
van Roon-Mom, WM	1
Vis, JC	1
Verbeek, MM	1
De Waal, RM	1
Ten Donkelaar, HJ	1
Kremer, HP	1
Araujo, DM	1
Cherry, SR	1
Tatsukawa, KJ	1
Toyokuni, T	1
Kornblum, HI	1
Nicniocaill, B	1
Haraldsson, B	1
Hansson, O	1
O'Connor, WT	1
Brundin, P	1
Barami, K	1
Hutchins, KD	1
Lyman, WD	1
Fezza, F	1
Cebeira, M	1
Bisogno, T	1
Milone, A	1
Bourne, JA	1
Hansen, HH	1
Berrendero, F	1
Pérez-Rosado, A	1
Manzanares, J	1
Bensadoun, JC	1
de Almeida, LP	1
Dréano, M	1
Aebischer, P	1
Déglon, N	1
Fujiyama, F	1
Stephenson, FA	1
Bolam, JP	1
McGeer, PL	2
McGeer, EG	2
Bennett, JP	4
Bylund, DB	2
Snyder, SH	2
Fahn, S	1
Coyle, JT	4
Schwarcz, R	3
Yoshida, M	2
Bonilla, E	2
Toru, M	1
Carolei, A	1
Del Castillo, G	1
Buchanan, J	1
Barbeau, A	1
Urquhart, N	2
Kennedy, J	2
Glaeser, BS	3
Vogel, WH	2
Oleweiler, DB	1
Mizuno, Y	1
Kartzinel, R	1
Terry, RD	1
Weiner, WJ	2
Achar, VS	1
Welch, KM	1
Chabi, E	1
Bartosh, K	1
Meyer, JS	1
Paulson, GW	2
Agid, Y	2
Kuran, W	1
Lenman, JA	1
Ferguson, IT	1
Fleming, AM	1
Herzberg, M	1
Robb, JE	1
Turnbull, MJ	1
Huizinga, JD	1
Teelken, AW	1
Muskiet, FA	1
vd Meulen, J	1
Wolthers, BG	1
Rosa, A	1
Stern, LZ	1
Wastek, GJ	1
McNamara, JO	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596]	Phase 2	33 participants (Actual)	Interventional	2005-11-30	Completed
Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI[NCT05232955]		40 participants (Anticipated)	Observational	2022-02-28	Not yet recruiting
Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI[NCT05233306]		60 participants (Anticipated)	Observational	2022-01-27	Recruiting
NMDA-Receptor Blockade in Huntington's Chorea[NCT00001930]	Phase 2	25 participants	Interventional	1999-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	0.005
Placebo	0.172

Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	-0.67
Placebo	1.23

Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	-0.113
Placebo	0.225

Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	0.386
Placebo	0.664

"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment

Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	-0.256
Placebo	-0.046

Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	-0.10
Placebo	1.50

Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	-0.227
Placebo	-0.170

Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	-0.54
Placebo	-0.06

"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment

Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Intervention	units on a scale (Least Squares Mean)
Citalopram	0.087
Placebo	0.405

Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment

Article	Year
Alteration of GABAergic neurotransmission in Huntington's disease. CNS neuroscience & therapeutics, 2018, Volume: 24, Issue:4 Topics: Animals; gamma-Aminobutyric Acid; Humans; Huntington Disease; Receptors, GABA-A; Synaptic Transmissi	2018
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review. Current neuropharmacology, 2019, Volume: 17, Issue:2 Topics: Acetylcholine; Adenosine; Animals; Basal Ganglia; Cannabinoids; Corpus Striatum; Dopamine; gamma-Ami	2019
Insights into GABA Open biology, 2018, 12-05, Volume: 8, Issue:12 Topics: Animals; Drug Discovery; gamma-Aminobutyric Acid; Humans; Huntington Disease; Molecular Targeted The	2018
Turning the heterogeneous into homogeneous: studies on selectively isolated GABAergic interneuron subsets. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2004, Volume: 22, Issue:7 Topics: Animals; Biomarkers; Brain; gamma-Aminobutyric Acid; Humans; Huntington Disease; Interneurons; Nerve	2004
Huntington's disease. A decade of progress. Neurologic clinics, 1984, Volume: 2, Issue:3 Topics: Brain; Chromosomes, Human, 1-3; gamma-Aminobutyric Acid; Genetic Counseling; Humans; Huntington Dise	1984
Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness. Advances in biochemical psychopharmacology, 1981, Volume: 29 Topics: Antipsychotic Agents; Brain Chemistry; Dyskinesia, Drug-Induced; Epilepsy; gamma-Aminobutyric Acid;	1981
Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder. The West Indian medical journal, 1981, Volume: 30, Issue:3 Topics: Amphetamine; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance	1981
Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications. Molecular and cellular biochemistry, 1981, Sep-25, Volume: 39 Topics: 4-Aminobutyrate Transaminase; Afferent Pathways; Aminocaproates; Animals; Basal Ganglia; Behavior, A	1981
GABA in the striatonigral and striatopallidal systems as moderator and mediator of striatal functions. Advances in neurology, 1984, Volume: 40 Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Catalepsy; Corpus Striatum; Diencephalon; gam	1984
Huntington's disease: new approaches to an old problem. The Robert Wartenberg lecture. Neurology, 1984, Volume: 34, Issue:8 Topics: Acetylcholine; Adult; Age Factors; Basal Ganglia; DNA; Dopamine; gamma-Aminobutyric Acid; Genes, Dom	1984
Pharmacology of GABA. Clinical neuropharmacology, 1982, Volume: 5, Issue:3 Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep	1982
[Toxic action of kainic acid as a model of Huntington chorea and epilepsy (review)]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1983, Volume: 83, Issue:5 Topics: Animals; Anticonvulsants; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Interactio	1983
The basal ganglia in extrapyramidal dysfunction. Brain research bulletin, 1983, Volume: 11, Issue:2 Topics: Basal Ganglia; Basal Ganglia Diseases; Corpus Striatum; Dyskinesia, Drug-Induced; Feedback; gamma-Am	1983
Huntington's disease: a generalized membrane defect. Life sciences, 1981, Mar-09, Volume: 28, Issue:10 Topics: Animals; Blood Platelets; Cell Membrane; Electron Spin Resonance Spectroscopy; Erythrocyte Aging; Er	1981
GABA system, GABA receptor agonists and dyskinesia. Modern problems of pharmacopsychiatry, 1983, Volume: 21 Topics: Basal Ganglia; Cholinergic Fibers; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Huma	1983
The current state of research with peripheral tissues in Huntington disease. Human genetics, 1984, Volume: 66, Issue:2-3 Topics: Antibody-Dependent Cell Cytotoxicity; Biopsy; Blood Platelets; Cell Division; Cell Membrane; Cell Mi	1984
Chemical pathology of Huntington's disease. Annual review of pharmacology and toxicology, 1980, Volume: 20 Topics: Acetylcholine; Aging; Behavior; Dopamine; gamma-Aminobutyric Acid; Humans; Huntington Disease; Neuro	1980
The neuropathology of GABA neurons in extrapyramidal disorders. Journal of neural transmission. Supplementum, 1980, Issue:16 Topics: Basal Ganglia Diseases; gamma-Aminobutyric Acid; Humans; Huntington Disease; Neurons; Parkinson Dise	1980
Presymptomatic and early detection in Huntington's disease. Annals of neurology, 1980, Volume: 8, Issue:4 Topics: Blood Platelets; Electrodiagnosis; Evoked Potentials; Eye Movements; gamma-Aminobutyric Acid; Geneti	1980
[Biogenic amines to the pathophysiology of involuntary movements and cerebellar ataxia (author's transl)]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 1981, Volume: 26, Issue:11 Topics: Adolescent; Biogenic Amines; Brain; Cerebellar Ataxia; Child; Child, Preschool; Dystonia; gamma-Amin	1981
SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS drug reviews, 2001,Winter, Volume: 7, Issue:4 Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop	2001
SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS drug reviews, 2001,Winter, Volume: 7, Issue:4 Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop	2001
SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS drug reviews, 2001,Winter, Volume: 7, Issue:4 Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop	2001
SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS drug reviews, 2001,Winter, Volume: 7, Issue:4 Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop	2001
Neurotransmitter interactions related to central dopamine neurons. Essays in neurochemistry and neuropharmacology, 1978, Volume: 3 Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Central Nervous System; Dopam	1978
[Abnormal neurotransmission in neurological diseases (author's transl)]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 1979, Volume: 24, Issue:2 Topics: Acetylcholine; Animals; Antiparkinson Agents; Corpus Striatum; Dementia; Dopamine; Female; gamma-Ami	1979
[Recent neurobiological and related pharmaco-therapeutic acquisitions in Huntington's chorea]. La Clinica terapeutica, 1979, Sep-30, Volume: 90, Issue:6 Topics: Amphetamine; Antipsychotic Agents; Brain; Butyrophenones; gamma-Aminobutyric Acid; Humans; Huntingto	1979
Progress in understanding Huntington's chorea. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1975, Volume: 2, Issue:2 Topics: Acetylcholine; Acetylcholinesterase; Basal Ganglia; Blood-Brain Barrier; Brain; Catecholamines; Caud	1975
[Physiology and pharmacology of extrapyramidal tract]. Nihon rinsho. Japanese journal of clinical medicine, 1975, Volume: 33, Issue:10 Topics: Acetylcholine; Basal Ganglia; Catecholamines; Caudate Nucleus; Cerebral Cortex; Corpus Striatum; Dop	1975
Dementia. A brief and selective review. Archives of neurology, 1976, Volume: 33, Issue:1 Topics: Alzheimer Disease; Basal Ganglia; Brain; Brain Chemistry; Caudate Nucleus; Creutzfeldt-Jakob Syndrom	1976
The pharmacology of choreatic movement disorders. Progress in neurobiology, 1976, Volume: 6, Issue:1 Topics: Acetylcholine; Acute Disease; Amphetamine; Chorea; Dopamine; gamma-Aminobutyric Acid; Hepatolenticul	1976
[Neuropharmacologic approach in Huntington's chorea]. Revue neurologique, 1975, Volume: 131, Issue:12 Topics: Acetylcholine; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Huntington Disease; Mod	1975
Biochemical approaches to dementia. Contemporary neurology series, 1977, Volume: 15 Topics: Adult; Aged; Alzheimer Disease; Animals; Brain; Cerebrovascular Circulation; Dementia; gamma-Aminobu	1977
Neurochemical findings in Huntington's chorea. Essays in neurochemistry and neuropharmacology, 1977, Volume: 1 Topics: Acetylcholine; Brain; Catecholamines; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Hunt	1977
The pathogensis and medical treatment of extrapyramidal disease. The Medical clinics of North America, 1979, Volume: 63, Issue:4 Topics: Adult; Athetosis; Basal Ganglia Diseases; Caudate Nucleus; Chorea; Corpus Striatum; Dopamine; Dopami	1979
Use of the neurotoxic agents kainic acid and tetanus toxin in the extrapyramidal system. Advances in cytopharmacology, 1979, Volume: 3 Topics: Animals; Brain; Cerebellum; Extrapyramidal Tracts; gamma-Aminobutyric Acid; Hippocampus; Huntington	1979
[The role of GABA neurons in some neurological and psychiatric disorders (author's transl)]. Lijecnicki vjesnik, 1979, Volume: 101, Issue:9 Topics: Brain; Epilepsy; gamma-Aminobutyric Acid; Humans; Huntington Disease; Neurons; Parkinson Disease; Sc	1979
Neurobiology and pharmacology of Huntington's disease. Life sciences, 1977, Jan-15, Volume: 20, Issue:2 Topics: Brain; Carnosine; Choline O-Acetyltransferase; Cholinergic Fibers; gamma-Aminobutyric Acid; Glutamat	1977
Postmortem studies of peptides in Alzheimer's disease and Huntington's disease. Research publications - Association for Research in Nervous and Mental Disease, 1986, Volume: 64 Topics: Alzheimer Disease; Basal Ganglia; Brain; Brain Chemistry; Cerebral Cortex; Choline O-Acetyltransfera	1986
Chorea. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1987, Volume: 14, Issue:3 Suppl Topics: Antipsychotic Agents; Cholinergic Fibers; Chorea; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid	1987
[A hypothesis for pharmacologic research on GABAergic approaches in Huntington chorea]. Annales pharmaceutiques francaises, 1989, Volume: 47, Issue:5 Topics: Animals; Central Nervous System; gamma-Aminobutyric Acid; Glutamates; Glycine; Humans; Huntington Di	1989
[Neurotransmitters in Huntington chorea (review)]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1985, Volume: 85, Issue:3 Topics: Acetylcholine; Basal Ganglia; Brain; Cell Membrane; Corpus Striatum; Dopamine; gamma-Aminobutyric Ac	1985
The endogenous opioid system in neurological disorders of the basal ganglia. Life sciences, 1985, Nov-04, Volume: 37, Issue:18 Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clonidine; Endorphins; gamma-Aminobutyric Aci	1985
Huntington's disease: genetics, chemical pathology, and management. Progress in medical genetics, 1985, Volume: 6 Topics: Acetylcholine; Age Factors; Brain; Cell Membrane; Chromosomes, Human, 4-5; Diagnosis, Differential;	1985
Gamma-vinyl GABA. General pharmacology, 1985, Volume: 16, Issue:5 Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Behavior, Animal; beta-Alanine;	1985
Cation shifts and excitotoxins in Alzheimer and Huntington disease and experimental brain damage. Progress in brain research, 1986, Volume: 70 Topics: Aged; Alzheimer Disease; Amino Acids; Animals; Brain; Brain Diseases; Calcium; Cations; gamma-Aminob	1986

Article	Year
Failure of isoniazid therapy in Huntington disease. Neurology, 1982, Volume: 32, Issue:10 Topics: Adult; Brain; Double-Blind Method; gamma-Aminobutyric Acid; Humans; Huntington Disease; Isoniazid; M	1982
Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington's disease. Life sciences, 1980, Apr-21, Volume: 26, Issue:16 Topics: Adult; Clinical Trials as Topic; Double-Blind Method; gamma-Aminobutyric Acid; Humans; Huntington Di	1980
Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease. Annals of neurology, 1981, Volume: 10, Issue:1 Topics: Adult; Clinical Trials as Topic; Double-Blind Method; gamma-Aminobutyric Acid; Humans; Huntington Di	1981
GABA and movement disorders. Advances in biochemical psychopharmacology, 1981, Volume: 30 Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced;	1981
Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology, 1976, Volume: 26, Issue:1 Topics: Adult; Aminobutyrates; Clinical Trials as Topic; Dopamine; Drug Evaluation; Drug Therapy, Combinatio	1976
Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Annals of neurology, 1978, Volume: 4, Issue:3 Topics: Activities of Daily Living; Adolescent; Adult; Clinical Trials as Topic; Cognition; Double-Blind Met	1978
Isoniazid therapy of Huntington disease. Neurology, 1979, Volume: 29, Issue:3 Topics: 4-Aminobutyrate Transaminase; Adult; Brain; Clinical Trials as Topic; Female; gamma-Aminobutyric Aci	1979
Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease. Journal of neurology, 1990, Volume: 237, Issue:5 Topics: Acetylcholinesterase; Adult; Aged; Aged, 80 and over; Analysis of Variance; Choline; Double-Blind Me	1990
Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease. Brain research, 1987, Apr-07, Volume: 408, Issue:1-2 Topics: Adult; Amino Acids; Clinical Trials as Topic; Double-Blind Method; gamma-Aminobutyric Acid; Histidin	1987

Article	Year
Mechanisms underlying the enhancement of γ-aminobutyric acid responses in the external globus pallidus of R6/2 Huntington's disease model mice. Journal of neuroscience research, 2020, Volume: 98, Issue:11 Topics: Animals; Disease Models, Animal; Electrophysiological Phenomena; Female; GABA Antagonists; GABA Plas	2020
The difficulty to model Huntington's disease in vitro using striatal medium spiny neurons differentiated from human induced pluripotent stem cells. Scientific reports, 2021, 03-25, Volume: 11, Issue:1 Topics: Action Potentials; Animals; Calcium; Case-Control Studies; Cell Culture Techniques; Cell Differentia	2021
Disease-modifying effects of ganglioside GM1 in Huntington's disease models. EMBO molecular medicine, 2017, Volume: 9, Issue:11 Topics: Animals; Behavior, Animal; Body Weight; Brain; Calcium-Binding Proteins; Disease Models, Animal; Dop	2017
Restoring GABAergic inhibition rescues memory deficits in a Huntington's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2018, 02-13, Volume: 115, Issue:7 Topics: Animals; Bumetanide; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Hippocampus; Humans; H	2018
A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. Human molecular genetics, 2018, 06-15, Volume: 27, Issue:12 Topics: Animals; Brain; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Gene Expression Re	2018
Striatal Direct and Indirect Pathway Output Structures Are Differentially Altered in Mouse Models of Huntington's Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2018, 05-16, Volume: 38, Issue:20 Topics: Animals; Cell Communication; Cell Membrane; Corpus Striatum; Electrophysiological Phenomena; Excitat	2018
Enhanced striatopallidal gamma-aminobutyric acid (GABA) Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:5 Topics: Animals; Corpus Striatum; Disease Models, Animal; Electric Stimulation; Electrophysiological Phenome	2019
Enhanced Na Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:6 Topics: Animals; Caudate Nucleus; Disease Models, Animal; gamma-Aminobutyric Acid; Humans; Huntington Diseas	2019
Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms. The Journal of cell biology, 2013, Sep-30, Volume: 202, Issue:7 Topics: Age Factors; Animals; Behavior, Animal; Blotting, Western; Brain; Chromatography, Liquid; Dopamine;	2013
Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3. Frontiers in neural circuits, 2013, Volume: 7 Topics: Animals; Anisoles; Astrocytes; Corpus Striatum; GABA Agonists; GABA Plasma Membrane Transport Protei	2013
Sub-chronic copper pretreatment reduces oxidative damage in an experimental Huntington's disease model. Biological trace element research, 2014, Volume: 162, Issue:1-3 Topics: Animals; Apomorphine; Copper; Disease Models, Animal; gamma-Aminobutyric Acid; Huntington Disease; L	2014
Cortical inhibitory deficits in premanifest and early Huntington's disease. Behavioural brain research, 2016, Jan-01, Volume: 296 Topics: Adult; Aged; Electromyography; Female; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male; Mi	2016
Neuroprotective Activity of Curcumin in Combination with Piperine against Quinolinic Acid Induced Neurodegeneration in Rats. Pharmacology, 2016, Volume: 97, Issue:3-4 Topics: Adenosine; Alkaloids; Animals; Antioxidants; Benzodioxoles; Brain; Catecholamines; Curcumin; Cytokin	2016
Essential fatty acid-rich diets protect against striatal oxidative damage induced by quinolinic acid in rats. Nutritional neuroscience, 2017, Volume: 20, Issue:7 Topics: Animals; Body Weight; Cholesterol; Corpus Striatum; Disease Models, Animal; Fatty Acids, Essential;	2017
Early GABAergic transmission defects in the external globus pallidus and rest/activity rhythm alteration in a mouse model of Huntington's disease. Neuroscience, 2016, 08-04, Volume: 329 Topics: Aging; Animals; Disease Models, Animal; Disease Progression; gamma-Aminobutyric Acid; Globus Pallidu	2016
Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation. Pharmacological reports : PR, 2017, Volume: 69, Issue:2 Topics: Animals; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Huntington	2017
Huntington's disease: modeling the gait disorder and proposing novel treatments. Journal of theoretical biology, 2008, Sep-21, Volume: 254, Issue:2 Topics: Basal Ganglia; Computer Simulation; Diazepam; GABA Modulators; Gait; gamma-Aminobutyric Acid; Glutam	2008
Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease. Neurochemical research, 2009, Volume: 34, Issue:7 Topics: Animals; Behavior, Animal; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Choline; Corpus Striatum;	2009
Two novel comments on the treatment of Huntington's disease. The Journal of neuropsychiatry and clinical neurosciences, 2009,Winter, Volume: 21, Issue:1 Topics: Basal Ganglia; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Huntington Disease; Models, Neurologi	2009
Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. Journal of chemical neuroanatomy, 2009, Volume: 37, Issue:4 Topics: Aged; Aged, 80 and over; Brain Mapping; Cannabinoid Receptor Modulators; Down-Regulation; Enkephalin	2009
Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. European journal of pharmacology, 2012, Jan-15, Volume: 674, Issue:2-3 Topics: Amines; Animals; Body Weight; Brain; Catalase; Cyclohexanecarboxylic Acids; GABAergic Neurons; Gabap	2012
Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiology of disease, 2012, Volume: 45, Issue:3 Topics: Action Potentials; Analysis of Variance; Animals; Benzoxazines; Brain; Disease Models, Animal; Drona	2012
Hyperglycemic chorea-ballism or acute exacerbation of Huntington's chorea? Huntington's disease unmasked by diabetic ketoacidosis in type 1 diabetes mellitus. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9 Topics: Adult; Brain; Chorea; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; DNA; Female; gamma-Aminobuty	2012
Transplantation of GABAergic cells derived from bioreactor-expanded human neural precursor cells restores motor and cognitive behavioral deficits in a rodent model of Huntington's disease. Cell transplantation, 2013, Volume: 22, Issue:12 Topics: Animals; Behavior, Animal; Cell Transdifferentiation; Cells, Cultured; Disease Models, Animal; Femal	2013
Tonic mGluR5/CB1-dependent suppression of inhibition as a pathophysiological hallmark in the striatum of mice carrying a mutant form of huntingtin. The Journal of physiology, 2013, Feb-15, Volume: 591, Issue:4 Topics: Animals; Corpus Striatum; gamma-Aminobutyric Acid; Huntingtin Protein; Huntington Disease; In Vitro	2013
[On what I learned from researches on Huntington's disease]. Rinsho shinkeigaku = Clinical neurology, 2001, Volume: 41, Issue:12 Topics: Animals; Corpus Striatum; gamma-Aminobutyric Acid; Humans; Huntington Disease; Inclusion Bodies; Neu	2001
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Journal of neurochemistry, 2003, Volume: 84, Issue:5 Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can	2003
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease. The European journal of neuroscience, 2003, Volume: 18, Issue:4 Topics: Acetylcholine; Animals; Convulsants; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; g	2003
Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Nov-26, Volume: 23, Issue:34 Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Str	2003
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. Molecular and cellular neurosciences, 2004, Volume: 25, Issue:1 Topics: Acetylcholine; Adenosine Triphosphate; Animals; Cell Respiration; Dose-Response Relationship, Drug;	2004
Can lesions of GPe correct HD deficits? Experimental neurology, 2004, Volume: 186, Issue:1 Topics: Animals; Disease Models, Animal; Enkephalins; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Hunt	2004
AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Molecular therapy : the journal of the American Society of Gene Therapy, 2004, Volume: 9, Issue:5 Topics: Animals; Brain-Derived Neurotrophic Factor; Calbindins; Choline O-Acetyltransferase; Corpus Striatum	2004
Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease. Neuroscience, 2004, Volume: 127, Issue:2 Topics: Animals; Biomarkers; Bromodeoxyuridine; Cell Death; Cell Differentiation; Cell Division; Cell Moveme	2004
Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease. Naunyn-Schmiedeberg's archives of pharmacology, 2004, Volume: 370, Issue:2 Topics: Amines; Animals; Anticonvulsants; Aza Compounds; Corpus Striatum; Cyclohexanecarboxylic Acids; Disea	2004
Induction of GABAergic phenotype in a neural stem cell line for transplantation in an excitotoxic model of Huntington's disease. Experimental neurology, 2004, Volume: 190, Issue:1 Topics: Animals; Cell Differentiation; Cell Line; Cell Proliferation; Cells, Cultured; Disease Models, Anima	2004
Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. Journal of neuroscience research, 2004, Dec-15, Volume: 78, Issue:6 Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; GABA Antagonists; gamma-Aminobut	2004
Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model. Neuroscience research, 2005, Volume: 52, Issue:3 Topics: Animals; Apomorphine; Behavior, Animal; Cell Count; Cells, Cultured; Corpus Striatum; Disease Models	2005
Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biological psychiatry, 2005, Jun-15, Volume: 57, Issue:12 Topics: Animals; Animals, Newborn; Cannabinoid Receptor Antagonists; Corpus Striatum; Drug Interactions; Ele	2005
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. Brain research, 2005, Jul-19, Volume: 1050, Issue:1-2 Topics: Animals; Brain Chemistry; Capsaicin; Convulsants; Disease Models, Animal; Dopamine; gamma-Aminobutyr	2005
Cell-cell interactions may be crucial in HD. The Lancet. Neurology, 2005, Volume: 4, Issue:7 Topics: Animals; Cell Communication; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Huntington Disease; M	2005
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D	2006
Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III). Neuroscience, 2005, Volume: 135, Issue:2 Topics: Analysis of Variance; Animals; Behavior, Animal; Blotting, Southern; Brain Injuries; Caspase 3; Casp	2005
Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. Pharmacology, biochemistry, and behavior, 2005, Volume: 82, Issue:3 Topics: Animals; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Huntington Disease; Male;	2005
Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neuroscience letters, 2006, Oct-30, Volume: 407, Issue:3 Topics: Amines; Animals; Apoptosis; Cells, Cultured; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Anta	2006
Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Human molecular genetics, 2008, Sep-01, Volume: 17, Issue:17 Topics: Animals; Basal Ganglia; Dopamine and cAMP-Regulated Phosphoprotein 32; Estradiol; Female; gamma-Amin	2008
GABA and benzodiazepine receptors in basal ganglia function. Neuroscience letters, 1984, Jun-29, Volume: 47, Issue:3 Topics: Animals; Basal Ganglia; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric	1984
Chemistry of Huntington's chorea. Lancet (London, England), 1980, May-24, Volume: 1, Issue:8178 Topics: Acetylcholine; Choline; Choline O-Acetyltransferase; Corpus Striatum; Dopamine; gamma-Aminobutyric A	1980
Benzodiazepine receptors: the effect of GABA on their characteristics in human brain and their alteration in Huntington's disease. Brain research, 1980, Oct-13, Volume: 199, Issue:1 Topics: Aged; Anti-Anxiety Agents; Flunitrazepam; gamma-Aminobutyric Acid; Humans; Huntington Disease; Putam	1980
Neurotransmitters and CNS disease. Dementia. Lancet (London, England), 1982, Nov-27, Volume: 2, Issue:8309 Topics: Acetylcholine; Aged; Alzheimer Disease; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; Dopa	1982
Neuronal [3H]benzodiazepine binding and levels of GABA, glutamate, and taurine are normal in Huntington's disease cerebellum. Journal of neurochemistry, 1983, Volume: 41, Issue:5 Topics: Amino Acids; Cerebellum; Flunitrazepam; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Haloperi	1983
[Lumbar cerebrospinal fluid levels of GABA, HVA and 5HIAA in various patients with choreic movement and effects with isoniazid treatment]. No to shinkei = Brain and nerve, 1983, Volume: 35, Issue:5 Topics: Acanthocytes; Adult; Aged; Atrophy; Brain Diseases; Chorea; gamma-Aminobutyric Acid; Homovanillic Ac	1983
Dopamine D-1 and D-2 receptors in Huntington's disease. European journal of pharmacology, 1983, Mar-25, Volume: 88, Issue:2-3 Topics: Aged; Brain; Female; gamma-Aminobutyric Acid; Humans; Huntington Disease; Kinetics; Male; Middle Age	1983
Gamma-aminobutyric acid (GABA) in cerebrospinal fluid. Acta medica Okayama, 1983, Volume: 37, Issue:3 Topics: Adult; Behcet Syndrome; Cerebellar Diseases; Cerebral Infarction; Dementia; Female; gamma-Aminobutyr	1983
Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease. Neurology, 1983, Volume: 33, Issue:9 Topics: Adult; Apomorphine; Arecoline; Dopamine; Female; gamma-Aminobutyric Acid; Growth Hormone; Humans; Hu	1983
Further characterization of in vitro conditions appropriate for GABA determination in human CSF: impact of acid deproteinization and freeze/thaw. Journal of neurochemistry, 1983, Volume: 41, Issue:4 Topics: Adult; Aged; Benzenesulfonates; Drug Stability; Female; Freezing; gamma-Aminobutyric Acid; Humans; H	1983
[Huntington chorea: report of 16 cases]. Arquivos de neuro-psiquiatria, 1983, Volume: 41, Issue:2 Topics: Adult; Aged; Brain Diseases; Chlorpromazine; Dementia; Diagnosis, Differential; Female; gamma-Aminob	1983
Parkinson's disease and benign essential tremor: somatostatin-like immunoreactivity in the cerebrospinal fluid. Advances in neurology, 1984, Volume: 40 Topics: Adult; Aged; Alzheimer Disease; Atrophy; Brain Diseases; Female; gamma-Aminobutyric Acid; Humans; Hu	1984
Therapeutic failure of GABA agonist treatment in Huntington's disease. Neurology, 1984, Volume: 34, Issue:5 Topics: gamma-Aminobutyric Acid; Humans; Huntington Disease; Isoxazoles; Oxazoles	1984
[Neurochemical abnormalities in Huntington's disease]. Harefuah, 1983, Apr-15, Volume: 104, Issue:8 Topics: 4-Aminobutyrate Transaminase; gamma-Aminobutyric Acid; Humans; Huntington Disease	1983
Huntington's disease: biochemical prediction by determination of GABA synthesis of cultured fibroblasts. Journal of neurology, 1984, Volume: 231, Issue:1 Topics: Cells, Cultured; Fibroblasts; gamma-Aminobutyric Acid; Humans; Huntington Disease; Radioligand Assay	1984
[Sleep in chronic chorea patients after therapy with sodium valproate]. Bollettino della Societa italiana di biologia sperimentale, 1984, May-30, Volume: 60, Issue:5 Topics: Adult; Chorea; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male; M	1984
Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. Brain research, 1984, Jul-30, Volume: 307, Issue:1-2 Topics: Adult; Age Factors; Aged; Cerebellar Ataxia; Dementia; Epilepsy; gamma-Aminobutyric Acid; Humans; Hu	1984
[Huntington chorea and neurotransmitters]. Nihon rinsho. Japanese journal of clinical medicine, 1984, Volume: 42, Issue:4 Topics: Basal Ganglia; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Huntington Disease	1984
Elevation of gamma-aminobutyric acid in human brain may increase dopaminergic neuronal function. Neuroscience letters, 1984, Sep-07, Volume: 50, Issue:1-3 Topics: Brain; Brain Chemistry; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Huntington Dis	1984
GABA receptor binding and endogenous inhibitors in normal human brain and Huntington's disease. Advances in biochemical psychopharmacology, 1980, Volume: 21 Topics: Animals; Brain; Cerebellum; Corpus Striatum; Frontal Lobe; GABA Antagonists; gamma-Aminobutyric Acid	1980
Substantia nigra gamma-aminobutyric acid receptors in Huntington's disease. Journal of neurochemistry, 1981, Volume: 37, Issue:2 Topics: Aged; Female; gamma-Aminobutyric Acid; Humans; Huntington Disease; Kinetics; Male; Middle Aged; Post	1981
Neurotoxicity of folates: implications for vitamin B12 deficiency and Huntington's chorea. Medical hypotheses, 1981, Volume: 7, Issue:7 Topics: Animals; Brain; Chemical Phenomena; Chemistry; Chiroptera; Folic Acid; gamma-Aminobutyric Acid; Huma	1981
Glutamic acid decarboxylase and gamma-aminobutyric acid in Huntington's disease fibroblasts and other cultured cells, determined by a [3H]muscimol radioreceptor assay. Journal of neurochemistry, 1981, Volume: 37, Issue:4 Topics: Carboxy-Lyases; Cells, Cultured; Fibroblasts; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Huma	1981
gamma-Aminobutyric acid receptors in normal human brain and Huntington disease. Neurology, 1982, Volume: 32, Issue:1 Topics: Brain; Caudate Nucleus; gamma-Aminobutyric Acid; Humans; Huntington Disease; Putamen; Receptors, Cel	1982
Quantitative autoradiography of neurotransmitter receptors in Huntington disease. Neurology, 1982, Volume: 32, Issue:12 Topics: Adult; Autoradiography; Brain; Female; Flunitrazepam; gamma-Aminobutyric Acid; Humans; Huntington Di	1982
An analysis of the cortical and striatal involvement in dyskinesia induced in rats by intracerebral injection of GABA-transaminase inhibitors and picrotoxin. European journal of pharmacology, 1980, Apr-04, Volume: 62, Issue:4 Topics: 4-Aminobutyrate Transaminase; Administration, Topical; Animals; Brain; Cerebral Cortex; Corpus Stria	1980
Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders. Archives of neurology, 1980, Volume: 37, Issue:6 Topics: Brain Chemistry; Cerebellar Diseases; Creatine Kinase; Dementia; Diet; Encephalitis; Epilepsy; gamma	1980
Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. Journal of the neurological sciences, 1980, Volume: 48, Issue:3 Topics: Brain; Female; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Huntington Disease; Male; S	1980
GABA and neuropsychiatric disorders. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1980, Volume: 7, Issue:3 Topics: Animals; Basal Ganglia; Central Nervous System Diseases; Epilepsies, Myoclonic; Epilepsies, Partial;	1980
Rats chronically injected with urine from Huntington's chorea patients do not striatal damage. Life sciences, 1981, Jun-22, Volume: 28, Issue:25 Topics: Amino Acids; Animals; Brain; Brain Chemistry; Choline O-Acetyltransferase; Corpus Striatum; Female;	1981
[Huntington's chorea]. Medicina, 1981, Volume: 41, Issue:1 Topics: gamma-Aminobutyric Acid; Humans; Huntington Disease	1981
Human CSF GABA concentrations: revised downward for controls, but not decreased in Huntington's chorea. Journal of neurochemistry, 1982, Volume: 38, Issue:3 Topics: Carbon Radioisotopes; Carnosine; gamma-Aminobutyric Acid; Humans; Huntington Disease; Reference Valu	1982
Huntington's chorea. Canadian Medical Association journal, 1982, Mar-15, Volume: 126, Issue:6 Topics: Baclofen; Canada; gamma-Aminobutyric Acid; Health Facilities; Humans; Huntington Disease; Hydroxybut	1982
Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain : a journal of neurology, 1993, Volume: 116 ( Pt 5) Topics: Adolescent; Adult; Aged; Basal Ganglia; Child; Enkephalin, Methionine; Female; gamma-Aminobutyric Ac	1993
Adult onset myoclonic Huntington's disease. Movement disorders : official journal of the Movement Disorder Society, 1993, Volume: 8, Issue:2 Topics: Adult; Atrophy; Cerebral Cortex; Corpus Striatum; Electric Stimulation; Electroencephalography; Elec	1993
Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat. Brain research, 1997, Dec-05, Volume: 778, Issue:1 Topics: Animals; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Excitatory Amino Acid Agonists;	1997
Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. Journal of neurochemistry, 1999, Volume: 72, Issue:4 Topics: Animals; Brain Chemistry; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid;	1999
Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. Neuroscience, 1999, Volume: 92, Issue:1 Topics: Activins; Animals; Calbindin 2; Choline O-Acetyltransferase; Corpus Striatum; gamma-Aminobutyric Aci	1999
The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. Experimental neurology, 1999, Volume: 159, Issue:1 Topics: Animals; Calbindin 2; Calbindins; Cell Count; Choline O-Acetyltransferase; Cholinergic Fibers; Corpu	1999
3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum. Neuropathology and applied neurobiology, 1999, Volume: 25, Issue:6 Topics: Animals; Corpus Striatum; gamma-Aminobutyric Acid; Glial Fibrillary Acidic Protein; Hindlimb; Huntin	1999
Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease. Experimental neurology, 2000, Volume: 166, Issue:2 Topics: Animals; Autoradiography; Benzazepines; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine A	2000
Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. The European journal of neuroscience, 2001, Volume: 13, Issue:1 Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; gamma-Aminobutyric Acid; Glutamic Acid; Huntin	2001
Neurotransmitter distribution in the second trimester fetal human corpus striatum. Neurological research, 2001, Volume: 23, Issue:1 Topics: Acetylcholine; Age Factors; Brain Tissue Transplantation; Corpus Striatum; Enkephalins; Female; Feta	2001
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport, 2001, Jul-20, Volume: 12, Issue:10 Topics: Animals; Basal Ganglia; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Disease Models,	2001
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse (New York, N.Y.), 2002, Volume: 44, Issue:1 Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Disease Mode	2002
Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. The European journal of neuroscience, 2001, Volume: 14, Issue:11 Topics: Acetylcholine; Animals; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Genetic Vectors; Hu	2001
Synaptic localization of GABA(A) receptor subunits in the substantia nigra of the rat: effects of quinolinic acid lesions of the striatum. The European journal of neuroscience, 2002, Volume: 15, Issue:12 Topics: Animals; Dendrites; Female; Functional Laterality; gamma-Aminobutyric Acid; Huntington Disease; Immu	2002
Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea. Journal of neurochemistry, 1976, Volume: 26, Issue:1 Topics: Acetylcholine; Acetylcholinesterase; Adolescent; Adult; Age Factors; Aged; Aminobutyrates; Brain; Ca	1976
Huntington's chorea. Changes in neurotransmitter receptors in the brain. The New England journal of medicine, 1976, Jun-10, Volume: 294, Issue:24 Topics: Alprenolol; Binding Sites; Binding, Competitive; Brain; Caudate Nucleus; Cerebral Cortex; Choline O-	1976
Biochemistry of the basal ganglia. Advances in neurology, 1976, Volume: 14 Topics: Adult; Animals; Basal Ganglia; Cats; Cerebellar Cortex; Cerebral Cortex; Dogs; Dopamine beta-Hydroxy	1976
Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature, 1976, Sep-16, Volume: 263, Issue:5574 Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Disease Models, Animal; Dopamine; gamma-Amino	1976
Alterations of brain neurotransmitter receptor binding in Huntington's chorea. Brain research, 1976, Nov-12, Volume: 116, Issue:3 Topics: Acetylcholine; Brain; Choline O-Acetyltransferase; gamma-Aminobutyric Acid; Globus Pallidus; Glutama	1976
Neurohumoral interactions and basal ganglia function and dysfunction. Research publications - Association for Research in Nervous and Mental Disease, 1976, Volume: 55 Topics: Acetylcholine; Basal Ganglia; Caudate Nucleus; Dopamine; Feedback; gamma-Aminobutyric Acid; Humans;	1976
[Basal ganglia lesions and neurotransmitters]. Nihon rinsho. Japanese journal of clinical medicine, 1978, Volume: 36, Issue:1 Topics: Acetylcholine; Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric Acid; Humans; Huntington Disease	1978
[Biochemical aspects of Huntington's disease]. Acta cientifica venezolana, 1977, Volume: 28, Issue:6 Topics: Acetylcholine; Dopamine; gamma-Aminobutyric Acid; Humans; Huntington Disease; Neurotransmitter Agent	1977
An animal model for Huntington's disease. Biological psychiatry, 1979, Volume: 14, Issue:2 Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Ac	1979
[Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry]. Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie = Archives suisses de neurologie, neurochirurgie et de psychiatrie, 1979, Volume: 125, Issue:2 Topics: 4-Aminobutyrate Transaminase; Basal Ganglia Diseases; Bicuculline; Dopamine; Dyskinesia, Drug-Induce	1979
Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet (London, England), 1979, Feb-03, Volume: 1, Issue:8110 Topics: Brain Chemistry; gamma-Aminobutyric Acid; Humans; Huntington Disease; Middle Aged; Nucleus Accumbens	1979
GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects. Journal of neurochemistry, 1975, Volume: 24, Issue:5 Topics: Adult; Aged; Aminobutyrates; Autopsy; Brain Chemistry; Carbon Radioisotopes; Carboxy-Lyases; Caudate	1975
GABA levels in cerebrospinal fluid of patients with Huntington's chorea: a preliminary report. Biochemical medicine, 1975, Volume: 12, Issue:4 Topics: Adult; Aged; Aminobutyrates; Amitriptyline; Chlorpromazine; Diazepam; Female; gamma-Aminobutyric Aci	1975
Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease. Neurology, 1976, Volume: 26, Issue:8 Topics: Aminobutyrates; Cerebrovascular Disorders; Dementia; Epilepsy, Post-Traumatic; Epilepsy, Temporal Lo	1976
Lioresal in Huntington's disease. Diseases of the nervous system, 1976, Volume: 37, Issue:8 Topics: Aminobutyrates; Baclofen; Dantrolene; Diazepam; Drug Evaluation; Gait; gamma-Aminobutyric Acid; Grow	1976
[Modern methods of treating Huntington's chorea]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1976, Aug-09, Volume: 31, Issue:32 Topics: gamma-Aminobutyric Acid; Haloperidol; Humans; Huntington Disease; Lithium; Methysergide; Physostigmi	1976
Sodium valproate in chorea. British medical journal, 1976, Nov-06, Volume: 2, Issue:6044 Topics: Aged; Brain; Female; Gait; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male; Movement; Vale	1976
Predictive tests in Huntington's disease. Research publications - Association for Research in Nervous and Mental Disease, 1976, Volume: 55 Topics: Age Factors; Electroencephalography; Eye Movements; Female; gamma-Aminobutyric Acid; Genetic Counsel	1976
Rational approaches to the pharmacotherapy of chorea. Research publications - Association for Research in Nervous and Mental Disease, 1976, Volume: 55 Topics: Acetylcholine; Chorea; Dopamine; Drug Evaluation; gamma-Aminobutyric Acid; Homovanillic Acid; Humans	1976
Sodium valproate in chorea. British medical journal, 1976, Dec-25, Volume: 2, Issue:6051 Topics: Adult; Aged; Brain Chemistry; gamma-Aminobutyric Acid; Humans; Huntington Disease; Middle Aged; Vale	1976
Uptake and release of GABA and GABA in Huntington's chorea [proceedings]. Psychopharmacology bulletin, 1977, Volume: 13, Issue:1 Topics: Aminobutyrates; Animals; Brain; Cats; gamma-Aminobutyric Acid; Humans; Huntington Disease; Rats	1977
Identification of GABA in human CSF by gas liquid chromatography and mass spectrometry. The New England journal of medicine, 1977, Mar-24, Volume: 296, Issue:12 Topics: Aminobutyrates; Chromatography, Gas; gamma-Aminobutyric Acid; Humans; Huntington Disease; Mass Spect	1977
Hemiballismus. The New England journal of medicine, 1977, Mar-31, Volume: 296, Issue:13 Topics: Aminobutyrates; Diencephalon; gamma-Aminobutyric Acid; Humans; Huntington Disease; Movement Disorder	1977
[Neurology in 1977]. La Revue du praticien, 1977, Jun-21, Volume: 27, Issue:35 Topics: Bromocriptine; Defense Mechanisms; Dopamine; Facial Paralysis; gamma-Aminobutyric Acid; Hemiplegia;	1977
Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. Archives of neurology, 1977, Volume: 34, Issue:11 Topics: Adolescent; Adult; Aged; Alzheimer Disease; Aminobutyrates; Child; Dementia; gamma-Aminobutyric Acid	1977
Glutamate neurotoxicity and Huntington's chorea. Nature, 1978, Feb-09, Volume: 271, Issue:5645 Topics: Animals; Corpus Striatum; gamma-Aminobutyric Acid; Glutamates; Huntington Disease; Injections; Kaini	1978
Isoniazid and Huntington's chorea. The New England journal of medicine, 1978, May-11, Volume: 298, Issue:19 Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Huntington Disease; Isoniazid; Rats; Valproic Acid	1978
Biochemical effects in man and rat of three drugs which can increase brain GABA content. Journal of neurochemistry, 1978, Volume: 30, Issue:4 Topics: Acetates; Adult; Amino Acids; Aminobutyrates; Aminooxyacetic Acid; Animals; Brain; gamma-Aminobutyri	1978
Pharmacology of Huntington's chorea. Personal experience. European neurology, 1977, Volume: 16, Issue:1-6 Topics: Acetates; Adult; Aminobutyrates; Blood Cell Count; Bromocriptine; Female; gamma-Aminobutyric Acid; H	1977
[Huntington's chorea--new development in biochemical theories]. Nihon rinsho. Japanese journal of clinical medicine, 1978, Volume: Suppl Topics: Adult; gamma-Aminobutyric Acid; Humans; Huntington Disease; Middle Aged	1978
[GABA system in the brain. Possible clinical and pharmacological aspects]. Ugeskrift for laeger, 1978, Jul-10, Volume: 140, Issue:28 Topics: Brain; Epilepsy; gamma-Aminobutyric Acid; Humans; Huntington Disease; Schizophrenia	1978
Mass spectrometric identification and selected ion monitoring quantitation of gamma-amino-butyric acid (GABA) in human lumbar cerebrospinal fluid. Journal of neurochemistry, 1978, Volume: 31, Issue:4 Topics: Bipolar Disorder; Chromatography, Gas; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Hu	1978
The brain in Huntington's chorea. Psychological medicine, 1978, Volume: 8, Issue:3 Topics: Age Factors; Alzheimer Disease; Atrophy; Basal Ganglia; Brain; Cell Survival; Dopamine; gamma-Aminob	1978
Inhibitors of GABA metabolism: implications for Huntington's disease. Annals of neurology, 1977, Volume: 2, Issue:4 Topics: 4-Aminobutyrate Transaminase; Alkynes; Aminocaproates; Aminocaproic Acid; Animals; Caudate Nucleus;	1977
Huntington's disease. Cerebrospinal fluid GABA levels in at-risk individuals. Archives of neurology, 1978, Volume: 35, Issue:11 Topics: Adolescent; Adult; Child; Female; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male	1978
Huntington's disease: current concepts of therapy. Journal of the American Geriatrics Society, 1979, Volume: 27, Issue:1 Topics: Acetylcholine; Adolescent; Adult; Butyrophenones; Child; Chlorpromazine; Dopamine Antagonists; gamma	1979
Long term treatment of Huntington disease with L-glutamate and pyridoxine. Neurology, 1978, Volume: 28, Issue:12 Topics: Adult; Brain; Female; gamma-Aminobutyric Acid; Glutamates; Humans; Huntington Disease; Long-Term Car	1978
Differential effects of agonal status on measurements of GABA and glutamate decarboxylase in human post-mortem brain tissue from control and Huntington's chorea subjects. Journal of neurochemistry, 1979, Volume: 33, Issue:3 Topics: Adolescent; Adult; Aged; Aging; Animals; Brain; Carboxy-Lyases; gamma-Aminobutyric Acid; Glutamate D	1979
GABA synthesis by cultured fibroblasts obtained from persons with Huntington's disease. Journal of neurochemistry, 1979, Volume: 33, Issue:5 Topics: Cell Division; Cells, Cultured; Female; Fibroblasts; gamma-Aminobutyric Acid; Glutamate Decarboxylas	1979
Sodium-independent, high-affinity binding of [3H]gamma-aminobutyric acid in human neurological disorders. Advances in experimental medicine and biology, 1979, Volume: 123 Topics: Binding, Competitive; Brain; Cerebellar Cortex; gamma-Aminobutyric Acid; Humans; Huntington Disease;	1979
GABA in Huntington's chorea, Parkinsonism and schizophrenia. Advances in experimental medicine and biology, 1979, Volume: 123 Topics: Animals; Body Temperature; Brain; Carboxy-Lyases; Death, Sudden; gamma-Aminobutyric Acid; Glutamate	1979
Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. The Journal of clinical endocrinology and metabolism, 1978, Volume: 47, Issue:6 Topics: Adult; Aged; Chronic Disease; Female; gamma-Aminobutyric Acid; Growth Hormone; Humans; Huntington Di	1978
Alterations in 3H-GABA binding in Huntington's chorea. Life sciences, 1977, Sep-01, Volume: 21, Issue:5 Topics: Aminobutyrates; Basal Ganglia; Brain; Cerebellar Cortex; Cerebral Cortex; gamma-Aminobutyric Acid; H	1977
Clinical, neuropathologic and pharmacologic aspects of Huntington's disease: correlates with a new animal model. Progress in neuro-psychopharmacology, 1977, Volume: 1, Issue:1-2 Topics: Animals; Brain; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Humans; Huntington	1977
Erythrocyte membrane alterations in Huntington disease: effects of gamma-aminobutyric acid. Journal of supramolecular structure, 1978, Volume: 9, Issue:1 Topics: Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Erythrocytes; gamma-Aminobutyric Acid; H	1978
An analysis of [3H]gamma-aminobutyric acid (GABA) binding in the human brain. Brain research, 1979, Mar-09, Volume: 163, Issue:1 Topics: Adolescent; Adult; Aged; Binding Sites; Binding, Competitive; Brain; Caudate Nucleus; Cerebellar Cor	1979
[3H]GABA binding in brains from Huntington's chorea patients: altered regulation by phospholipids? Science (New York, N.Y.), 1979, Sep-14, Volume: 205, Issue:4411 Topics: Cerebellar Cortex; gamma-Aminobutyric Acid; Humans; Huntington Disease; Kinetics; Membrane Lipids; P	1979
Letter: Low GABA levels in CSF in Huntington's chorea. The New England journal of medicine, 1975, May-08, Volume: 292, Issue:19 Topics: gamma-Aminobutyric Acid; Humans; Huntington Disease	1975
The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex. Annals of neurology, 1992, Volume: 32, Issue:4 Topics: Age Factors; Aged; Animals; Aspartic Acid; Brain Chemistry; Cholecystokinin; Female; gamma-Aminobuty	1992
On chorea: possible neuronal mechanisms. Clinical neurology and neurosurgery, 1992, Volume: 94 Suppl Topics: Animals; Brain Mapping; Corpus Striatum; Dopamine; Enkephalins; gamma-Aminobutyric Acid; Humans; Hun	1992
Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. The New England journal of medicine, 1992, May-28, Volume: 326, Issue:22 Topics: Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Biological Transport; Brain; Female; gamma-A	1992
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 1991, Volume: 11, Issue:6 Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Atrophy; Biogenic Amines; Cerebra	1991
Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex. Neuroscience letters, 1990, May-18, Volume: 113, Issue:1 Topics: Adult; Aged; Caudate Nucleus; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; Female; gamma-	1990
[3H]nipecotic acid binding to gamma-aminobutyric acid uptake sites in postmortem human brain. Journal of neurochemistry, 1990, Volume: 55, Issue:1 Topics: Aged; Aging; Binding Sites; Brain; Cadaver; Female; gamma-Aminobutyric Acid; Hippocampus; Humans; Hu	1990
Brain GABA levels in asymptomatic Huntington's disease. The New England journal of medicine, 1990, Sep-06, Volume: 323, Issue:10 Topics: Brain Chemistry; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male; Middle Aged	1990
Pallidal GABA and chorea in Huntington's disease. Journal of neural transmission. General section, 1990, Volume: 81, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Chorea; Dopamine; Female; gamma-Aminobutyric Acid; Globus Pallidus;	1990
Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neuroscience letters, 1987, Jul-22, Volume: 78, Issue:2 Topics: Brain Chemistry; gamma-Aminobutyric Acid; Globus Pallidus; Glutamates; Glutamic Acid; Hippocampus; H	1987
Cerebral cation shifts and amino acids in Huntington's disease. Archives of neurology, 1986, Volume: 43, Issue:12 Topics: Adult; Aged; Amino Acids; Brain; Cations; Female; Frontal Lobe; gamma-Aminobutyric Acid; Humans; Hun	1986
Huntington's disease: studies on brain free amino acids. Life sciences, 1988, Volume: 42, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Aspartic Acid; Brain; Female; gamma-Aminobutyric Acid;	1988
Striatal dopamine and homovanillic acid in Huntington's disease. Journal of neural transmission, 1986, Volume: 65, Issue:2 Topics: Aged; Caudate Nucleus; Corpus Striatum; Dopamine; Female; gamma-Aminobutyric Acid; Homovanillic Acid	1986
Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea. Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:2 Topics: Adult; Aged; Carnosine; Dipeptides; Female; Friedreich Ataxia; gamma-Aminobutyric Acid; Humans; Hunt	1987
[Disorders of nocturnal sleep in Huntington chorea]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1985, Volume: 85, Issue:3 Topics: Adult; Brain; Dreams; Electroencephalography; Female; gamma-Aminobutyric Acid; Humans; Huntington Di	1985
Free and conjugated CSF and plasma GABA in Huntington's chorea. Acta neurologica Scandinavica, 1986, Volume: 74, Issue:4 Topics: Adult; Aging; Brain; Female; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male; Middle Aged;	1986
Is a circulating neurotoxin involved in the pathogenesis of Huntington's chorea? Journal of the neurological sciences, 1985, Volume: 67, Issue:3 Topics: Animals; Biological Assay; Choline O-Acetyltransferase; Corpus Striatum; gamma-Aminobutyric Acid; Hu	1985
Brain amino compounds in a Huntington's disease patient on isoniazid therapy. Neurology, 1985, Volume: 35, Issue:5 Topics: Adult; Brain Chemistry; Carnosine; Caudate Nucleus; Cerebellar Nuclei; gamma-Aminobutyric Acid; Huma	1985
Editorial: Dopamine and G.A.B.A. in Huntington's chorea. Lancet (London, England), 1974, Nov-09, Volume: 2, Issue:7889 Topics: Aminobutyrates; Blood Platelets; Brain; Butyrophenones; Dopamine; gamma-Aminobutyric Acid; Humans; H	1974
Gamma-aminobutyric acid and nervous system function--a perspective. Biochemical pharmacology, 1974, Oct-01, Volume: 23, Issue:19 Topics: Aminobutyrates; Animals; Behavior, Animal; Brain; Brain Chemistry; Carboxy-Lyases; Central Nervous S	1974
Gamma-aminobutyric acid: drug-induced elevation in monkey brain. Journal of neurochemistry, 1974, Volume: 23, Issue:2 Topics: Acetates; Aminobutyrates; Animals; Brain; Carbon Radioisotopes; Carboxy-Lyases; gamma-Aminobutyric A	1974
Elevation of brain gamma-aminobutyric acid in the mouse by L-2,4-diaminobutyric acid. Transactions of the American Neurological Association, 1974, Volume: 99 Topics: Amino Acids, Diamino; Aminobutyrates; Animals; Brain; Choline; Female; gamma-Aminobutyric Acid; Hunt	1974
Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain : a journal of neurology, 1974, Volume: 97, Issue:3 Topics: Acetyltransferases; Adolescent; Adult; Age Factors; Aged; Animals; Autopsy; Basal Ganglia; Brain Che	1974

gamma-aminobutyric acid and Huntington Disease